Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IO Biotech, Inc.IOBT · Entity 8764 | Chief Financial Officer | April 02, 2025 | April 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IO Biotech, Inc.
Report date April 02, 2025 · Filed April 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2035-04-02 | Direct | 215,000 |
Reported balance
After 2025-04-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-02 · Grant · Acquired 215,000 · Balance 215,000 F1: One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 02, 2025 Filed Apr 4, 2025 20:16 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 215,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0000905148-25-001095 · form4.xml · derivative · entry 1 Sullivan Amy · CIK 0001887865 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2035-04-02 F1 · derivative.exercise_date: One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. Read SEC document |
| December 23, 2024 Filed Dec 23, 2024 23:53 UTC | IO Biotech, Inc. IOBT · Entity 8764 | PurchaseCommon Stock | 10,250 | $0.83 | $8,482.90 |
DisclosureSEC source: 0000905148-24-003410 · form4.xml · nonDerivative · entry 1 Sullivan Amy · CIK 0001887865 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,632 F1 · price: The transaction was executed in multiple trades in prices ranging from $0.7861 to $0.90, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 20:24 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 280,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0000905148-24-000969 · form4.xml · derivative · entry 1 Sullivan Amy · CIK 0001887865 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2034-03-15 F1 · derivative.exercise_date: One-fourth of these options vest on March 15, 2025, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control. Read SEC document |
| August 09, 2023 Filed Aug 10, 2023 00:41 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantWarrants (Right to Buy) · Derivative | 49,382 | $0.13 Strike: $2.47 | $6,172.75 |
DisclosureSEC source: 0001140361-23-038879 · form4.xml · derivative · entry 2 Sullivan Amy · CIK 0001887865 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,382 Underlying: Common Stock · 49,382 shares Expires not disclosed F1 · derivative.expiration_date: These Warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition of the Issuer, as defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023. Read SEC document |
| August 09, 2023 Filed Aug 10, 2023 00:41 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantCommon Stock | 49,382 | $1.90 | $93,825.80 |
DisclosureSEC source: 0001140361-23-038879 · form4.xml · nonDerivative · entry 1 Sullivan Amy · CIK 0001887865 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,382 Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 20:26 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001140361-23-013076 · form4.xml · derivative · entry 1 Sullivan Amy · CIK 0001887865 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2033-03-20 F1 · derivative.exercise_date: One-fourth of these options vest on March 20, 2024, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause within 24 months of a change of control. Read SEC document |
| March 17, 2023 Filed Mar 20, 2023 21:35 UTC | IO Biotech, Inc. IOBT · Entity 8764 | PurchaseCommon Stock | 25,000 | $2.32 | $58,017.50 |
DisclosureSEC source: 0001140361-23-012596 · form4.xml · nonDerivative · entry 1 Sullivan Amy · CIK 0001887865 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · price: The transaction was executed in multiple trades in prices ranging from $2.18 to $2.46, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 20:54 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 288,152 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001567619-22-018617 · doc1.xml · derivative · entry 1 Sullivan Amy · CIK 0001887865 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,152 Underlying: Common Stock · 288,152 shares Expires 2032-10-17 F1 · derivative.exercise_date: One-fourth of these options vest on 10/15/2023, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service by the Issuer without cause within 24 months of a change of control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.